Drugs / AlloStim
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04441047 | Jul 2021 → Mar 2023 | COVID-19, acute respiratory distress syndrome, influenza, pneumonia +1 | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01923233 | Nov 2014 → Jun 2015 | hepatocellular carcinoma | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02018419 | Mar 2014 | breast cancer | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01995227 | Dec 2013 → Feb 2018 | hepatocellular carcinoma | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01065441 | Dec 2010 → Dec 2012 | breast cancer, colorectal cancer, melanoma, non-small cell lung carcinoma +3 | Michael Har-Noy | Completed | No outcome recorded |
| Phase 1/2 | NCT00558675 | Dec 2010 → Dec 2012 | leukemia, plasma cell myeloma | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06557278 | Nov 2026 → Jun 2028 | colorectal cancer | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04444622 | Jul 2021 → Mar 2025 | colorectal cancer | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02380443 | Sep 2016 → Mar 2018 | colorectal cancer | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02409524 | Jul 2016 → Jun 2017 | adult hepatocellular carcinoma | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01998542 | Jan 2016 → Jun 2017 | head and neck squamous cell carcinoma | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05033522 | Aug 2023 → Nov 2026 | hepatocellular carcinoma | Mirror Biologics, Inc. | Suspended | No outcome recorded |
| Phase 2/3 | NCT01741038 | Dec 2017 → Dec 2019 | colorectal cancer | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLOSTIM | “Safety and Efficacy of ALLOSTIM® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly Adults” NCT04441047 ↗ |
| Known as | AlloStim-TM | “the adjuvant is intentionally mis-matched immune cells (AlloStim-TM) engineered to produce inflammatory cytokines.” NCT01065441 ↗ |
| Action | Restore | “restore cellular immune function” PMID 40432075 ↗ Apr 2025 |
| Modality | Cell therapy | “The immune cells are living CD4+ memory Th1-like T-cells (T-Stim) that are differentiated from precursors purified from normal donor blood.” NCT00558675 ↗ |
| Route | Intravenous | “Single intravenous infusion of AlloStim” NCT00558675 ↗ |